Merck licenses NASH, diabetes compound from NGM

Merck & Co. Inc. (NYSE:MRK) exercised an option to license exclusive, worldwide rights to MK-3655

Read the full 156 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE